Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+ T cells in the tumor loci and enhanced anti-tumor effects.
Interleukin-2 (IL-2) has been shown to promote tumor-specific T-cell proliferation and differentiation but systemic administration of IL-2 results in significant toxicity. Therefore, a strategy that can specifically deliver IL-2 to the tumor location may alleviate concerns of toxicity. Because NKG2D...
Main Authors: | Tae Heung Kang, Chih-Ping Mao, Liangmei He, Ya-Chea Tsai, Katherine Liu, Victor La, T-C Wu, Chien-Fu Hung |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3324421?pdf=render |
Similar Items
-
The NKG2D receptor in tumor immunosurveillance and immunoevasion
by: Oppenheim, David Evan
Published: (2007) -
Impairment of NKG2D-Mediated Tumor Immunity by TGF-β
by: Mariya Lazarova, et al.
Published: (2019-11-01) -
NKG2D Ligands in Tumor Immunity: Two Sides of a Coin
by: Jennifer eWu, et al.
Published: (2015-03-01) -
Tumor-derived CSF-1 induces the NKG2D ligand RAE-1δ on tumor-infiltrating macrophages
by: Thornton W Thompson, et al.
Published: (2018-05-01) -
Control of Tumor Initiation by NKG2D Naturally Expressed on Ovarian Cancer Cells
by: Xin Cai, et al.
Published: (2017-06-01)